Actively Recruiting
Evaluating Imaging Biomarkers for Monitoring and Treatment of Myofascial Pain with Chemical Injection and Dry Needling
Led by Washington University School of Medicine · Updated on 2026-09-03
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating imaging biomarkers to better understand myofascial pain and assess their ability to track treatment responses and predict clinical outcomes. This Phase 2 randomized clinical trial builds on earlier findings that identified potential imaging markers linked to myofascial pain in the neck and shoulder areas. The study focuses on adults experiencing this type of pain with active trigger points. Participants will undergo advanced imaging tests including MRI, surface electromyography sEMG, and fiber-optic imaging. After these assessments, they will be randomly assigned to receive either a local chemical injection containing a mixture of lidocaine and bupivacaine or a dry needling procedure at the trigger points. The trial includes two visits about two weeks apart to complete imaging and patient questionnaires. During the study, participants will be closely monitored through imaging and self-reported outcomes to evaluate changes related to treatment. The primary outcome involves analyzing data collected from the two visits, each lasting 3 to 4 hours. The research team aims to understand how well these imaging biomarkers detect treatment effects and predict longer-term clinical responses, with the study concluding by August 2027.
CONDITIONS
Brief Title
Multi-modal Imaging of Myofascial Pain - Phase 2
Research Team
A
Andre Guthrie, BS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here